Core Viewpoint - Hai Jiaya Medical (06078.HK) reported a significant decline in revenue and net profit for the year ending December 31, 2025, primarily due to macroeconomic factors and local healthcare policy adjustments [4][5]. Financial Performance - The company achieved revenue of RMB 4.009 billion, a year-on-year decrease of 9.8% - Net profit fell sharply by 73.0% to RMB 162 million, largely due to a RMB 283 million impairment and provision related to Etern Group Ltd. - Despite profit pressures, operating cash flow reached a record high of RMB 950 million, up 34.4% year-on-year - The company's interest-bearing debt decreased by RMB 343 million, a decline of 12.3% [4][5]. Business Development - The core oncology business showed stability, with over 102,000 surgeries performed, and the proportion of high-level surgeries increased by 6.4 percentage points year-on-year - The international medical business made significant progress, with Chongqing Hai Jiaya Hospital providing services to patients from Southeast Asia and opening a two-story ward - The company plans to replicate its international medical business model in more suitable hospitals, expanding into areas such as early cancer screening and comprehensive treatment [6]. Network Expansion and Technology Integration - As of March 2026, the company managed or operated 17 comprehensive hospitals focused on oncology, with one additional tertiary hospital under construction - The company is actively exploring AI applications in medical scenarios, including AI-assisted personalized precision radiotherapy and imaging diagnosis - AI technology is also being utilized in supply chain and financial management to optimize inventory and enhance efficiency, along with the launch of an AI customer service system for patient engagement [7][8].

Group 1 - The medical health ETF Taikang (159760) rose by 0.68% as of July 3, 2025, with the index it tracks, the National Certificate Public Health and Medical Health Index (980016), increasing by 1.01% [1] - Key stocks in the sector include Zhenhua Cell (688520) up 19.99%, Huahai Pharmaceutical (600521) up 10.01%, and Changchun High-tech (000661) up 9.05% [1] - The WAIC 2025 event will be held in Shanghai from July 26-28, focusing on innovations in diagnosis and treatment, AI drug development, and featuring over 30 medical products [1] Group 2 - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, aiming to transition China from a "generic drug powerhouse" to an "innovative drug stronghold" [2] - The National Certificate Public Health and Medical Health Index reflects the market performance of listed companies in the public health and medical health industry in A-shares [2] - As of May 30, 2025, the top ten weighted stocks in the index accounted for 52.46%, including companies like Heng Rui Medicine (600276) and WuXi AppTec (603259) [2]